Status:
RECRUITING
NeoRad Breast Cancer Study
Lead Sponsor:
Bielefeld University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NAC...
Detailed Description
The standard of care for high-risk breast cancer consists of neoadjuvant chemotherapy and surgery followed by postoperative whole breast/chest wall irradiation+/- an additional boost (= irradiation re...
Eligibility Criteria
Inclusion
- Histologically proven invasive, unilateral breast cancer
- Indication for radiotherapy
- Indication for neoadjuvant chemotherapy (+/- antibody treatment or other targeted therapies) in accordance with national and international guidelines
- Female
- Informed consent for the trial signed by the patient
- Hormone receptor and HER2 status: no restrictions
- All grades G1-G3
- Age ≥ 18 years at the time of informed consent
- Performance status ≤ 2
- No pre-existing conditions that prohibit therapy
Exclusion
- Neoadjuvant treatment solely with endocrine therapy
- Bilateral breast cancer
- Pregnancy or lactation
- Prior radiotherapy of the thorax
- Connective tissue disease, including rheumatoid arthritis and thromboangiitis obliterans
- Pre-existing symptomatic chronic lung disease (fibrosis, pneumoconiosis, adult-onset allergies, such as farmer's lung, severe lung emphysema, COPD °III)
- Cardiac comorbidities: symptomatic coronary heart disease, prior heart attack, heart failure NYHA ≥II or AHA ≥C, pacemaker, and/or implanted defibrillator
- Malignoma except basalioma or in-situ-carcinomas in complete response
- Distant metastasis
- Plexopathies of the arm of the treated side
- Stiffness of the shoulder of the arm of the side of the breast cancer of any origin (e.g. following a road accident)
- Lymph edema ≥°II of the arm at the side of the breast cancer
- Other medical conditions that prohibit the neoadjuvant radiotherapy (i.e. Expected non-compliance, etc.)
- Male patients
- Patients who have previously been assessed for chemotherapy response
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2034
Estimated Enrollment :
1826 Patients enrolled
Trial Details
Trial ID
NCT04261244
Start Date
February 1 2024
End Date
March 31 2034
Last Update
May 7 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Marien-Krankenhaus Ahaus
Ahaus, Germany, 48683
2
Hochtaunus-Kliniken
Bad Homburg, Germany, 61352
3
Sana Klinikum Lichtenberg
Berlin, Germany, 10365
4
St. Agnes-Hospital
Bocholt, Germany, 46397